Category Archives: Neuroscience

Combat related trauma is significantly affecting U.S. military veterans compared to other military populations across the globe. As many as 20 percent of the U.S. military veterans who served in Iraq and Afghanistan and up to 30 percent of those who fought in the Vietnam War will suffer from Post-Traumatic Stress Disorder (PTSD) in aRead more

For the estimated 30 million people worldwide who have Alzheimer’s disease, progress toward understanding and treating this most prevalent form of dementia is frustratingly slow. The few approved drugs address only the condition’s symptoms, though scores of drugs to prevent onset or alter the disease’s course are now under study. From high screen failure ratesRead more

We worked on a Phase II study of a drug to treat Fragile X syndrome that, like most rare work we do, was a challenge from the start. Fragile X is a rare and not fully understood genetic disorder, typically resulting from an expansion of the CGG triplet repeat within the Fragile X mental retardation 1 (FMR1) geneRead more

DURHAM, N.C., SEPTEMBER 5, 2017 — Sponsors and CROs can forge stronger relationships by pursuing long-term partnerships that value collaboration over transactions. Premier Research’s top neuroscientist will discuss how when she hosts a session at Outsourcing Clinical Trials New England in Boston. Krista Armstrong, Vice President and Head of Neuroscience, will describe best practices forRead more

This is Part Two of our series on the increasingly high placebo response that is plaguing clinical trials in analgesia and psychiatry. Read the other parts here. Analgesic and psychiatric drug development is facing an enormous problem: rising placebo responses in randomized controlled trials (RCTs) threaten the ability of pharmaceutical companies to successfully identify novelRead more

Sponsors often face significant challenges in collecting robust, quality data that demonstrates the safety and efficacy of investigative psychiatric drugs. However, before these problems can be solved, they must be understood. Be sure to keep these four issues in mind when mapping out strategies for ensuring quality data collection in psychiatric clinical trials. 1. ThereRead more

DURHAM, N.C., November 10, 2016 — Researchers developing treatments for neurodegenerative disorders face some of the biggest hurdles in planning and conducting clinical drug trials. Get advice on navigating this difficult terrain by attending a Premier Research webinar on Tuesday, November 15. Neurodegenerative Disease Research: Steps to a Successful Clinical Trial will describe a complexRead more

DURHAM, N.C., October 28, 2016 — STARR Coalition, an organization dedicated to treatment, advocacy, research, and recovery in mental health, named Premier Research CRO of the Year at its annual STARR Meeting in Boca Raton, Florida. The group cited Premier Research for its longstanding partnership in supporting the coalition’s mission to serve the mental healthRead more

DURHAM, N.C., October 26, 2016 — Premier Research’s lead strategist will participate in a panel discussion on the evolving landscape for investigator sites at CNS Summit 2016 in Boca Raton, Florida. Krista Armstrong, Vice President of Strategic Development, will join colleagues in addressing topics such as: Advantages and disadvantages of site consolidation Site selection and strategicRead more

DURHAM, N.C., SEPTEMBER 1, 2016 — In a perfect world, clinical drug trials draw conclusive results from objective observations. But when the real world falls short of perfection by one of these criteria or both, you may need to make other plans. It’s a common occurrence in psychiatry drug trials, and managing the risks willRead more

Phone Us Now
Email Us Now